Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
COVID-19
Cilgavimab
Immunocompromised
Monoclonal antibodies
Preexposure prophylaxis
SARS-CoV-2
Tixagevimab
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
18
05
2022
revised:
15
07
2022
accepted:
16
07
2022
pubmed:
5
8
2022
medline:
25
11
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
Immunocompromised patients have an increased risk of a severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis during the Omicron wave in France. This was an observational multicentre cohort study of immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis between December 28, 2021 and March 31, 2022. Patients received tixagevimab/cilgavimab 150/150 mg intramuscularly if they had impaired vaccine response and a high risk of severe form of COVID-19. Tixagevimab/cilgavimab was administered to 1112 immunocompromised patients. After a median (range) follow-up of 63 (49-73) days, COVID-19 was confirmed in 49/1112 (4.4%) ≥5 days after treatment. During the study period, mean weekly incidence rate was 1669 in 100 000 inhabitants in Ile-de-France and 530 in 100 000 among patients who received tixagevimab/cilgavimab prophylaxis. Among infected patients, 43/49 (88%) had a mild-to-moderate form and 6/49 (12%) had a moderate-to-severe form of COVID-19. Patients with moderate-to-severe illnesses were less likely to have received early therapies than patients with mild forms (53.5% vs. 16.7% respectively) and 2/49 (4%) patients died from COVID-19. Our study reported a low rate of infections and severe illnesses among immunocompromised patients treated with tixagevimab/cilgavimab. A global preventive strategy including vaccines, preexposure prophylaxis with monoclonal antibodies, and early therapies might be effective to prevent severe forms of COVID-19 among severely immunocompromised patients.
Identifiants
pubmed: 35926762
pii: S1198-743X(22)00383-4
doi: 10.1016/j.cmi.2022.07.015
pmc: PMC9340091
pii:
doi:
Substances chimiques
tixagevimab
0
cilgavimab
1KUR4BN70F
Antibodies, Monoclonal
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1654.e1-1654.e4Informations de copyright
Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Lancet Rheumatol. 2021 Jun;3(6):e419-e426
pubmed: 33786454
BMJ. 2022 Mar 17;376:o722
pubmed: 35301227
Sci Transl Med. 2022 May 18;14(645):eabn8543
pubmed: 35380448
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
Kidney Int. 2022 Apr;101(4):824-825
pubmed: 35157894
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Kidney Int. 2022 Jun;101(6):1290-1293
pubmed: 35421508
JAMA. 2022 Jan 18;327(3):207-208
pubmed: 34964833
Am J Transplant. 2022 Nov;22(11):2675-2681
pubmed: 35713984